Sugi Predict

Sugi Predict / Compounds / SCHEMBL15401196

SCHEMBL15401196

SCHEMBL15401196

N#Cc1cccc(-c2c[nH]c3ncnc(N4CCCC4)c23)c1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 10)

geneUniProtsupporting neighboursconfidence
▸ LRRK2 Q5S007 19/20 1.00
▸ MST1 P26927 1/20 0.84
▸ STK4 Q13043 1/20 0.84
▸ STK3 Q13188 1/20 0.84
▸ STK26 Q9P289 1/20 0.84
▸ MAP4K1 Q92918 2/20 0.78
▸ PRKCQ Q04759 1/20 0.78
▸ JAK2 O60674 1/20 0.76
▸ JAK1 P23458 1/20 0.76
▸ JAK3 P52333 1/20 0.76

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15401845 0.99 LRRK2 (1.00) LRRK2MST1STK4STK3STK26
SCHEMBL30552996 0.91 LRRK2 (1.00) LRRK2MST1STK4STK3STK26
SCHEMBL15401353 0.91 LRRK2 (1.00) LRRK2MST1STK4STK3STK26
SCHEMBL29429971 0.91 LRRK2 (1.00) LRRK2MST1STK4STK3STK26
SCHEMBL15400864 0.89 LRRK2 (1.00) LRRK2MST1STK4STK3STK26
SCHEMBL15400668 0.89 LRRK2 (1.00) LRRK2MST1STK4STK3STK26
SCHEMBL15401091 0.89 LRRK2 (1.00) LRRK2MST1STK4STK3STK26
SCHEMBL15400713 0.88 LRRK2 (1.00) LRRK2MST1STK4STK3STK26
SCHEMBL15401274 0.88 LRRK2 (1.00) LRRK2MST1STK4STK3STK26
SCHEMBL15401752 0.88 LRRK2 (1.00) LRRK2MAP4K1PRKCQJAK2JAK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9156845-B2 4-(substituted amino)-7H-pyrrolo[2,3-d] pyrimidines as LRRK2 inhibitors PFIZER INC. (US) 2015-10-13 — — US claimed
EP-2867236-A1 NOVEL 4-(SUBSTITUTED-AMINO)-7H-PYRROLO[2,3-d]PYRIMIDINES AS LRRK2 INHIBITORS Pfizer Inc. (US) 2015-05-06 — — EP claimed
WO-2014001973-A1 NOVEL 4-(SUBSTITUTED-AMINO)-7H-PYRROLO[2,3-d]PYRIMIDINES AS LRRK2 INHIBITORS PFIZER INC. (US) 2014-01-03 — — WO claimed
US-20140005183-A1 Novel 4-(Substituted Amino)-7H-Pyrrolo[2,3-d] Pyrimidines As LRRK2 Inhibitors PFIZER (US) 2014-01-02 — — US claimed
US-11661461-B2 Phospho-Rab antibodies, assays and methods of use thereof DENALI THERAPEUTICS INC. (US) 2023-05-30 — — US disclosed
US-20210147573-A1 PHOSPHO-RAB ANTIBODIES, ASSAYS AND METHODS OF USE THEREOF DENALI THERAPEUTICS INC. (US) 2021-05-20 — — US disclosed
WO-2018232278-A2 PHOSPHO-RAB ANTIBODIES, ASSAYS AND METHODS OF USE THEREOF DENALI THERAPEUTICS INC. (US) 2018-12-20 — — WO disclosed
EP-2867236-B1 NOVEL 4-(SUBSTITUTED-AMINO)-7H-PYRROLO[2,3-D]PYRIMIDINES AS LRRK2 INHIBITORS PFIZER (US) 2017-06-14 — — EP disclosed
EP-2867236-B1 NOVEL 4-(SUBSTITUTED-AMINO)-7H-PYRROLO[2,3-D]PYRIMIDINES AS LRRK2 INHIBITORS PFIZER (US) 2017-06-14 — — EP disclosed
US-9642855-B2 Substituted pyrrolo[2,3-d]pyrimidines as LRRK2 inhibitors PFIZER INC. (US) 2017-05-09 — — US disclosed
US-9642855-B2 Substituted pyrrolo[2,3-d]pyrimidines as LRRK2 inhibitors PFIZER INC. (US) 2017-05-09 — — US disclosed
US-9642855-B2 Substituted pyrrolo[2,3-d]pyrimidines as LRRK2 inhibitors PFIZER INC. (US) 2017-05-09 — — US disclosed
US-20150366874-A1 Novel 4-(Substituted Amino)-7H-Pyrrolo[2,3-d]Pyrimidines As LRRK2 Inhibitors PFIZER INC. (US) 2015-12-24 — — US disclosed
US-20150366874-A1 Novel 4-(Substituted Amino)-7H-Pyrrolo[2,3-d]Pyrimidines As LRRK2 Inhibitors PFIZER INC. (US) 2015-12-24 — — US disclosed
US-9156845-B2 4-(substituted amino)-7H-pyrrolo[2,3-d] pyrimidines as LRRK2 inhibitors PFIZER INC. (US) 2015-10-13 — — US disclosed
US-9156845-B2 4-(substituted amino)-7H-pyrrolo[2,3-d] pyrimidines as LRRK2 inhibitors PFIZER INC. (US) 2015-10-13 — — US disclosed
US-9156845-B2 4-(substituted amino)-7H-pyrrolo[2,3-d] pyrimidines as LRRK2 inhibitors PFIZER INC. (US) 2015-10-13 — — US disclosed
EP-2867236-A1 NOVEL 4-(SUBSTITUTED-AMINO)-7H-PYRROLO[2,3-d]PYRIMIDINES AS LRRK2 INHIBITORS Pfizer Inc. (US) 2015-05-06 — — EP disclosed
WO-2014001973-A1 NOVEL 4-(SUBSTITUTED-AMINO)-7H-PYRROLO[2,3-d]PYRIMIDINES AS LRRK2 INHIBITORS PFIZER INC. (US) 2014-01-03 — — WO disclosed
US-20140005183-A1 Novel 4-(Substituted Amino)-7H-Pyrrolo[2,3-d] Pyrimidines As LRRK2 Inhibitors PFIZER (US) 2014-01-02 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210147573-A1 PHOSPHO-RAB ANTIBODIES, ASSAYS AND METHODS OF USE THEREOF RAB10, GTPBP10, RABL3 LRRK2 16/4885MST1 1047/4885STK4 1542/4885
US-20150366874-A1 Novel 4-(Substituted Amino)-7H-Pyrrolo[2,3-d]Pyrimidines As LRRK2 Inhibitors LRRK2, PARK7, BRCA1 LRRK2 1/4885MST1 3178/4885STK4 246/4885
US-11661461-B2 Phospho-Rab antibodies, assays and methods of use thereof RAB10, GTPBP10, RAB8A LRRK2 19/4885MST1 1196/4885STK4 1853/4885
US-20140005183-A1 Novel 4-(Substituted Amino)-7H-Pyrrolo[2,3-d] Pyrimidines As LRRK2 Inhibitors LRRK2, PARK7, BRCA1 LRRK2 1/4885MST1 3178/4885STK4 246/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.